БИБЛИОГРАФИЯ

Allen S et al. (2003). Treatment of chronic hepati­tis C in a state correctional facility. Annals of Internal Medicine, 138: 187-191.

Altice FL, Khoshnood K, Eicher A, Pinell V (1996).

Altice FL, Friedland GH (1998). The era of adher­ence to HIV therapy. Annals of Internal Medicine, 129(6): 503-505.

Altice FL, Mostashari F, Friedland GH (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome, 28: 47-58.

American College of Physicians, National Commission on Correctional Health Care, and American Correctional Health Services Association (1992). The Crisis in Correctional Health Care: The Impact of the National Drug Control Strategy on Correctional Health Services. Annals of Internal Medicine, 117(1): 72-77.

American Thoracic Society, CDC and Infectious Diseases Society of America (2003). Treatment of Tuberculosis. Morbidity and Mortality Weekly Report 52 (RR11); 1-77.

Babudieri S, Aceti A, D¹Offizi GP, Carbonara S, Starnini G (2000). Directly observed therapy to treat HIV infection in prisoners. JAMA, 284(2): 179-180.

Babudieri S, Pintus A, Maida I, Starnini G, Rezza G (2005). Does counseling increase sustained benefit of HAART among prison inmates after release to the community? Clinical Infectious Diseases, 40: 321-322.

Bobrik A et al. (2005). Prison health in Russia: the larger picture.

Journal of Public Health Policy, 26: 30-59.

Boutwell A, Rich JD (2004). HIV infection behind bars. Clinical Infectious Diseases, 38: 1761-1763. Bradford Hill A (1965). The environment and dis­ease: association or causation. Procedures of the Royal Society of Medicine, 58: 295-300.

Brewer TF (1991).

Centers for Disease Control and Prevention (1999). Decrease in AIDS-related mortality in a state correctional system - New York, 1995-1998. Morbidity and Mortality Weekly Report, 47: 1115­1117.

Centers for Disease Control and Prevention (2003). Prevention and control of infections with hepatitis viruses in correctional settings. Morbidity and Mortality Weekly Report, 53(No. RR-1): 1-44.

Cheever LW (2004). Adherence to HIV therapies. In: Tools for Grantees: A Guide to Primary Care for People with HIV/AIDS. U.S. Department of Health and Human Services, 2004 edition.

Clarke S, Keenan E, Ryan M (2002). Directly observed antiretroviral therapy for injecting drug users with HIV. The AIDS Reader 12(305-7): 412­416.

Coetzee D et al. (2004). Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS, 18(6): 887-895.

Department of Health and Human Services (2006). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. October 10, 2006.

Dolan J, Kite B, Aceijas C, Stimson GV (2007). HIV in prison in low-income and middle-income countries. Lancet Infectious Diseases, 7 : 32-43.

Drucker E et at. (1998). Measuring harm reduc­tion: the effects of needle and syringe exchange programmes and methadone maintenance on the ecology of HIV. (Review). AIDS, 12 (Suppl. A): S217-230.

Editorial (1991). Health care for prisoners: impli­cations of «Kalk's refusal.» The Lancet, 337: March 16: 647-648.

Edwards S, Tenant-Flowers M, Buggy J, Hulme N, Easterbrook P (2001). Issues in the management of prisoners infected with HIV-1: the King's College Hospital HIV prison service retrospective cohort study. British Medical Journal, 322: 398-399.

Farley J et al (2005). Hepatitis C treatment in a Canadian federal correctional population: Preliminary feasibility and outcomes. International Journal of Prisoner Health, 1(1): 13-18.

Farley J et al.

Farrell M et al. (2005). Effectiveness of drug dependence treatment in HIV prevention. International Journal of Drug Policy.

Federal Bureau of Prisons (2005). Guidelines for the prevention and treatment of viral hepatitis. Washington, DC: BOP, October2005.

Fischl M et al. (2000). Impact of directly observed therapy on outcomes in HIV clinical trials. [abstract 71]. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco). Alexandria, VA: Foundation for Retroviruses and Human Health.

Fischl M et al. (2001). Impact of directly observed therapy on long-term outcomes in HIV clinical tri­als [abstract 528]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Foundation for Retroviruses and Human Health.

Flanigan TP et al. (1996). A prison release pro­gram for HIV-positive women: linking them to health services and community follow-up. American Journal of Public Health, 86: 886-887.

Floridia M et al. (2000). Hospitalizations and costs of treatment for protease inhibitor-based regi­mens in patients with very advanced HIV-infec- tion (CD4 50/mm3). HIV Clin Trials, 1: 9-16.

Gallego O et al. (2003). High rate of resistance to antiretroviral drugs among HIV-infected prison inmates. Med Sci Monit, 9(6): CR217-221.

Glaser JB, RB Greifinger (1993). Correctional health care: A public health opportunity. Ann Int Med, 118: 139-145.

Haley D, Scheyett A, Golin C, Kaplan A, Parker S et al. (2006). Perceptions of release among incar­cerated HIV-infected persons and implications for practice: The UNC Bridges to Good Health and Treatment (BRIGHT) Project Qualitative Substudy. Poster presentation no THPE0717 at the XVI International AIDS Conference, Toronto, Canada, August 2006.

Harding T (1997). Do prisons need special health policies and programs? International Journal of Drug Policy, 8(1): 22-30.

Hassim A (2006). The '5 star' prison hotel? The right of access to ARV treatment for HIV positive prisoners in South Africa. International Journal of Prisoner Health, 2(3): 157-171.

Hayton P, Boyington J (2006). Prisons and health reforms in England and Wales. American Journal of Public Health, 96(10): 1730-1733.

Howard TR & Campbell WA (2004). Positive toold for HIV+ prisoners. In: Program and abstracts of XV International AIDS Conference, 11-16 July, Bangkok, Thailand. Abstract no WePeE6856.

Hoxie N et al. (1990). HIV seroprevalence and the acceptance of voluntary HIV testing among newly incarcerated male prison inmates in Wisconsin. American Journal of Public Health, 80(9): 1129-1131.

Jacobs S (1995). AIDS in correctional facilities: Current status of legal issues critical to policy development.

Journal of Criminal Justice, 23(3): 209-221.

Kennedy SS et al. (2004). Improving access to and utilization of health and social services for HIV-infected jail and prison releasees: evaluation results from the Corrections Demonstration Project funded by the Centers for Disease Control and Prevention (CDC) and Health Resources and Services Administration (HRSA). The XV International AIDS Conference (Poster Exhibition Abstract no. ThPeE7996).

Kim JY et al. (1997). Successful community fol­low-up and reduced recidivism of HIV positive women prisoners.

Journal of Correctional Health Care, 4: 1-9.

Kirkland LR, Fischl MA, Tashima KT, Paar D, Gensler T et al. (2002). Response to Lamivudine- Zidovudine plus Abacavir twice daily in antiretro­viral-naive, incarcerated patients with HIV infec­tion taking directly observed treatment. Clinical Infectious Diseases, 34: 511-518.

Lavalle C et al. (2000). Reduction in hospitaliza­tion costs, morbidity, disability, and mortality in patients with AIDS treated with protease inhibitors. Arch Med Res, 31: 515-519.

Liddicoat RV, Zheng H, Internicola J, Werner BG, Kazianis A et al. (2006). Implementing a routine, voluntary HIV testing program in a Massachusetts County Prison.

Lucas GM et al. (2004). Directly administeredan- tiretroviral therapy in an urban methadone main­tenance clinic: a nonrandomized comparative study. Clinical Infectious Diseases, 38: S409-413.

Macalino GE et al. (2004). Hepatitis C infection and incarcerated populations.

International Journal of Drug Policy, 15: 103-114.

Mackenzie AR, Laing RB, Urbaniak SJ, Molyneaux PJ, Douglas JG, Smith CC (1999). J Infect 38(2): 107-110.

Maruschak L (2001). HIV in Prisons, 2000. Washington, DC: US Dept of Justice, Bureau of Justice Statistics Bulletin.

Mattick RP et al. (2002). Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence (Cochrane review).

The Cochrane Library, Issue 4.

Moscatello G, Campello P, Benettucci JA (2003). Bloodborne and sexually transmitted infections in a hospital in Buenos Aires, Argentina. Clinical Infectious Diseases, 37(Supplement 5): S343-347.

Mostashari F et al. (1998). Acceptance and adherence with antiretroviral therapy among HIV- infected women in a correctional facility. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology, 18: 341-348.

National Commission on Correctional Health Care (2005). Administrative management of HIV in correctional institutions. [Position statement - first adopted on Nov 8, 1987; revised, Oct 9, 2005]. Chicago, The Commission.

Open Society Institute (2004). Breaking down barriers. Lessons on providing HIV treatment to injection drug users. New York, International Harm Reduction Programme, Open Society Institute.

Palella FJ et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338: 853-860.

Palepu A et al. (2003). Alcohol use and incarcer­ation adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.

Palepu A et al. (2004). Initiating highly active anti- retorviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.

Antivir Ther, 9(5): 713-719.

Palombi L et al. (2004). One year of HAART in Mozambique: survival, virological, and immuno­logical results of DREAM project in adults and children. In: Program and abstracts of the XI Conference on Retroviruses and Opportunistic Infections. February 8-11, San Francisco. Abstract 148.

Paterson DL et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133:21-30.

Patterson S et al. (2000). Drug-susceptible Tb outbreak in a state correctional facility housing HIV-infected inmates - South Carolina, 1999­2000. Morbidity and Mortality Weekly Review, 49(46): 1041-1044.

Pontali E, Papa L, Toscanini F, Levati A, Lugani C et al. (2004). Use of antiretroviral drugs in correc­tional facilities [Abstract P34]. Seventh International Congress on Drug Therapy in HIV Infection, 14-18 November 2004, Glasgow, UK.

Pontali E (2005). Antiretroviral treatment in cor­rectional facilities. HIV Clinical Trials, 6(1): 25-37. Ramratnam B et al. (1997). Former prisoners' views on mandatory HIV testing during incarceration. Journal of Correctional Health Care, 4: 155-164.

Saiz de la Hoya-Zamacola P, Marco-Mourino A, Clemente-Ricote G, Portilla-Sogorb J et al. (2006). Expert recommendations for the diagno­sis and treatment of chronic hepatitis C infection in the prison setting.

Gastroenterol Hepatol, 29(9): 551-559.

Simooya O, Sanjobo N (2006). Challenges and opportunities for scaling up HIV/AIDS care in pris­ons: A case study from Zambia. Oral presentation no TUAX0102 at the XVI International AIDS Conference, Toronto, Canada, August 2006.

Skolnick AA (1998). Correctional and community health care collaborations. Journal of the American Medical Association, 279: 98-99.

Soto Blanco JM, Perez JR, March JC (2005). Adherence to antiretroviral therapy among HIV- infected prison inmates (Spain).

Int J STD AIDS, 16(2): 133-138.

Soto Blanco JM, Perez JR, De Labry Lima AO, Recio JM et al. (2005). Adherence to antiretroviral treatment in prisons. AIDS Research and Human Retroviruses, 21(8): 683-688.

Spaulding AC et al. (2002). Human immunodefi­ciency virus in correctional facilities: a review. Clinical Infectious Diseases, 35: 305-312.

Spaulding AC, Weinbaum CM, Lau D, Sterling R, Seeff LB et al. (2006). A framework for manage­ment of hepatitis C in prisons. Annals of Internal Medicine, 144: 762-769.

Springer SA et al. (2004). Effectiveness of anti­retroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community.

Clinical Infectious Diseases, 38: 1754-1760.

Springer SA, Altice FL (2005). Managing HIV/AIDS in correctional settings.

Current HIV/AIDS Reports 2(4): 165-170.

Srisuphanthavorn M, Chayatub B, Chua A, Ngamnee V, Cavallier P, Zachariah R, Wilson D (2006). Antiretroviral treatment can be successful within a prison setting: The experience from Bangkwang Central Prison, Thailand. Poster presentation no THPE0167 at the XVI International AIDS Conference, Toronto, Canada, August 2006.

Stephenson BL, Wohl DA, Golin CE, Tien H-C, Stewart P, Kaplan AH (2005). Effect of release from prison and re-incarceration on the viral loads of HIV-infected individuals.

Public Health Reports, 120(1): 84-88.

Sulkowski MS, Thomas DL, Chaisson RE and Moore RD (2000). Hepatotoxicity associated with antiretroviral therapy in adults infected with the human immunodeciency virus and the role of hepatitis C or B virus infection. Journal of the American Medical Association, 283: 74-80.

UNAIDS (1997). Prisons and AIDS: UNAIDS point of view. Geneva: UNAIDS.

UNAIDS, WHO (2004). UNAIDS/WHO Policy Statement on HIV Testing. Geneva: UNAIDS/WHO.

UNODC, WHO and UNAIDS (2006). HIV/AIDS Prevention, Care, Treatment and Support in Prison Settings. A Framework for an Effective National Response. New York, Vienna & Geneva: United Nations Office on Drugs and Crime, World Health Organization and Joint United Nations Programme on HIV/AIDS.

Vallabhaneni S, Macalino E, Reinert SE, Schwartzapfel B, Wolf FA, Rich JD (2006). Prisoners favour hepatitis C testing and treat­ment. Epidemiology and Infection, 134: 243-248.

Vigilante KC et al. (1999). Reduction in recidivism of incarcerated women through primary care peer counseling and discharge planning. J Womens Health, 8: 409-415.

White BL, Wohl DA, Hays RD, Golin CE et al. (2006). A pilot study of health beliefs and atti­tudes concerning measures of antiretroviral adherence among prisoners receiving directly observed antiretroviral therapy. AIDS Patient Care and STDs, 20(6): 408-417.

Winarso I, Irawati I, Eka B, Nevendorff L et al. (2006). Indonesian National Strategy for HIV/AIDS control in prisons: A public health approach for prisoners. International Journal of Prisoner Health, 2(3): 243-249.

Wohl D et al. (2000). Adherence to directly observed therapy of antiretrovirals in a state prison system [abstract 357]. In: proceedings of the 38^th annual meeting of the Infectious Diseases Society of America (Philadelphia). Alexandria, VA: Infectious Diseases Society of America.

Wohl et al. (2003). Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clin Infect Dis, 36: 1572-1576.

Wohl D et al. (2004). Access to HIV care and anti­retroviral therapy following release from prison. 11^th Conference on Retroviruses and Opportunistic Infections, 8-11 February, abstract 859.

Wohl DA, Stephenson B, Schyette A, Golin C, Earp J, McKay T, Haley D, Kaplan A (2006). A randomized trial of a case management interven­tion to improve access to care, reduce transmis­sion risk behavior and recidivism in HIV-infected prisoners following release: The BRIGHT Study. Poster presentation no THPE0784 at the XVI International AIDS Conference, Toronto, Canada, August 2006.

Wood E et al. (2003). Expanding access to HIV antiretroviral therapy among marginalized popula­tions in the developed world. AIDS, 17(17): 2419­2427.

Wood E, Hogg RS, Yip B, et al. (2003b). Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral thera­py when the CD4+ cell count is 0.200 to 0.350x109 cells/mL. Annals of Internal Medicine, 39: 810-816.

WHO (1993). WHO Guidelines on HIV infection and AIDS in prisons. Geneva: WHO (WHO/GPA/DIR/93.3).

WHO & International Committee of the Red Cross (2000). Tuberculosis Control in Prisons. A Manual for Programme Managers. Geneva: WHO.

WHO (2005). Evidence for action on HIV/AIDS and injecting drug use. Policy brief: Antiretroviral therapy and injecting drug users. Geneva: WHO.

WHO (2006). Antiretroviral therapy for HIV infec­tion in adults and adolescents: towards universal access - Recommendations for a public health approach. Geneva: WHO.

WHO (2006b). HIV/AIDS Treatment and Care for Injecting Drug Users. Clinical Protocol for the WHO European Region. Copenhagen: WHO Europe Regional Office.

WHO, UNAIDS (2007). Guidance on Provider-ini­tiated HIV Testing and Counselling in Health Facilities. Geneva: WHO.

World Health Organization, (2007). Status Paper on Prisons and Tuberculosis. Copenhagen: WHO Europe Regional Office.

World Health Organization, UNODC, & UNAIDS (2007). Effectiveness of Interventions to Manage HIV in Prisons - Opioid Substitution Therapies and Other Drug Dependence Treatment. Evidence for Action Technical Paper. Geneva: WHO.